Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PHASE2 | ACTIVE NOT_RECRUITING | 22 | — | — | Mar 18, 2021 | Jun 1, 2026 | Sep 18, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment (carboplatin, pembrolizumab) | EXPERIMENTAL | Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial. |
| Name | Type | Description |
|---|---|---|
| Carboplatin | DRUG | Given IV |
| Pembrolizumab | BIOLOGICAL | Given IV |
| Computed Tomography | PROCEDURE | Undergo CT |
| Magnetic Resonance Imaging | PROCEDURE | Undergo MRI |
| Biospecimen Collection | PROCEDURE | Undergo blood sample collection |
Inclusion Criteria: * Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy * Have a cancer antigen (CA)-125 that normalized after first-line therapy * CA-125 increased to more than twice the upper lim...